Markets

TG Therapeutics (TGTX) Catches Eye: Stock Surges 20.8% in Session - Tale of the Tape

TG Therapeutics, Inc. ( TGTX ) was a big mover last session, as the company saw its shares rise nearly 21% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock is now up 86.08% over the past one-month time frame.

This med products stock witnessed 2 downward revisions over the past 30 days. The Zacks Consensus Estimate also moved down over the same time frame, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's move higher lasts.

TG Therapeutics has a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.

However, some better-ranked stocks in the same sector include Cardica Inc. ( CRDC ), ICU Medical, Inc. ( ICUI ) and NeuroMetrix Inc. ( NURO ). All these stocks hold a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

TG THERAPEUTICS (TGTX): Free Stock Analysis Report

CARDICA INC (CRDC): Free Stock Analysis Report

ICU MEDICAL INC (ICUI): Free Stock Analysis Report

NEUROMETRIX INC (NURO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ICUI NURO TGTX

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More